Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Using PRP and Cord Blood in Treatment of Covid -19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04393415
Recruitment Status : Not yet recruiting
First Posted : May 19, 2020
Last Update Posted : May 26, 2020
Sponsor:
Information provided by (Responsible Party):
Aljazeera Hospital

Brief Summary:
covid - 19 is a critical viral infection that affects humans

Condition or disease Intervention/treatment Phase
Virus Combination Product: stem cells Not Applicable

Detailed Description:
Covid -19 pandemic started was declared in 2020

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: the Effect of PRP and Cord Blood in Improving the Symptoms of Covid-19
Estimated Study Start Date : May 25, 2020
Estimated Primary Completion Date : July 25, 2020
Estimated Study Completion Date : August 1, 2020

Arm Intervention/treatment
Active Comparator: patients receiving cord blood stem cells Combination Product: stem cells
giving stem cells to patients with covid - 19

No Intervention: patients not receiving cord blood stem cells
Active Comparator: patients receiving Platelet rich plasma Combination Product: stem cells
giving stem cells to patients with covid - 19




Primary Outcome Measures :
  1. the number of patients with positive covid 19 who will improve after receiving stem cells [ Time Frame: 2 weeks ]
    patients with positive covid 19 who will improve after receiving stem cells



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with positive covid -19 and has symptoms and isolated in the hospital

Exclusion Criteria:

  • patients with negative test for covid -19

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04393415


Contacts
Layout table for location contacts
Contact: Mahmoud Alalfy, PhD 01002611058 mahmoudalalfy@ymail.com
Contact: Mahmoud Alalfy, PhD 0102611058 mahmoudalalfy@ymail.com

Locations
Layout table for location information
Egypt
Aljazeera( Al Gazeera) hospital
Giza, Egypt
Sponsors and Collaborators
Aljazeera Hospital
Investigators
Layout table for investigator information
Principal Investigator: Mahmoud Alalfy, PhD Algezeera hospitaland National Research Centre ,Egypt
Layout table for additonal information
Responsible Party: Aljazeera Hospital
ClinicalTrials.gov Identifier: NCT04393415    
Other Study ID Numbers: covid -19
First Posted: May 19, 2020    Key Record Dates
Last Update Posted: May 26, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No